When is entresto going generic?

Short answer: there isn’t a generic Entresto available yet in the U.S., and there isn’t a firm public date for when one will come.

What affects the timing
- Generic entry depends on patent protection and regulatory exclusivities. If the last patent on sacubitril/valsartan (or on its use/formulation) and any data exclusivities expire without successful patent challenges, a generic could enter after that.
- For Entresto, those protections extend well into the 2030s, so there isn’t a near-term date for generics in the U.S. Brand-name versions or authorized alternatives may remain dominant for years.

Other markets
- Some other countries may have different patent statuses or earlier generic entries, depending on local patents and approvals.

What you can do
- If you want the current official status, check the FDA’s Orange Book entry for sacubitril/valsartan (Entresto) to see the listed patents and their expiration dates.
- If you’re trying to reduce costs now, talk with your prescriber or pharmacist about patient programs or alternative medications that may be appropriate, and whether a generic option might be available in your country.

Would you like me to look up the latest Orange Book details or provide guidance on how to check the patent status yourself?